Evaluating the impact of age on immune checkpoint therapy biomarkers

(Cell Reports 36, 109599-1–109599-12.e1–e4; August 24, 2021) In the originally published version of this article, Hariharan Easwaran should have been listed as a corresponding author. The designation is now applied here and with the article online. The production team apologizes for the error. Evaluating the impact of age on immune checkpoint therapy biomarkersErbe et al.Cell ReportsAugust 24, 2021In BriefErbe et al. use multi-omics databases to evaluate biomarkers that are used to predict the response of patients with cancer to ICB in the context of aging. Erbe et al. find that biomarkers associated with ICB response are enriched in tumors from older patients relative to their younger counterparts. Full-Text PDF Open Access